The safety of treatments for tobacco use disorder

Melissa A. Little, Jon O. Ebbert

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Tobacco continues to be a leading cause of preventable morbidity and mortality in the world. First-line pharmacotherapies for the treatment of tobacco use disorder include nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. We provide an overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder.Areas covered: Randomized clinical trials published in English up to July 2015 were identified and reviewed through searches of PUBMED using the terms nicotine replacement therapy, bupropion SR, varenicline, smoking, and tobacco cessation.Expert opinion: Nicotine replacement has few contraindications and side effects and can be recommended to almost all tobacco users. Bupropion SR should be used with caution in patients with bipolar disorder or liver or kidney disease, and alternative treatments should be considered for patients with a history of seizures or who are at risk for seizures. The only contraindication for varenicline is an allergy to the medication, and nausea is the most common side effect. Varenicline can be used safely in patients with cardiovascular disease. Varenicline can be used in patients with stable psychiatric disease and safety can be ensured through close clinical monitoring.

Original languageEnglish (US)
Pages (from-to)333-341
Number of pages9
JournalExpert Opinion on Drug Safety
Volume15
Issue number3
DOIs
StatePublished - Mar 3 2016

Fingerprint

Tobacco Use Disorder
Bupropion
Safety
Nicotine
Tobacco
Seizures
Tobacco Use Cessation
Therapeutics
Drug Therapy
Expert Testimony
Kidney Diseases
Smoking Cessation
Bipolar Disorder
Nausea
Psychiatry
Liver Diseases
Hypersensitivity
Cardiovascular Diseases
Randomized Controlled Trials
Varenicline

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

The safety of treatments for tobacco use disorder. / Little, Melissa A.; Ebbert, Jon O.

In: Expert Opinion on Drug Safety, Vol. 15, No. 3, 03.03.2016, p. 333-341.

Research output: Contribution to journalReview article

Little, Melissa A. ; Ebbert, Jon O. / The safety of treatments for tobacco use disorder. In: Expert Opinion on Drug Safety. 2016 ; Vol. 15, No. 3. pp. 333-341.
@article{9938d3e1862f4119a5c8c5dfdd73af2f,
title = "The safety of treatments for tobacco use disorder",
abstract = "Introduction: Tobacco continues to be a leading cause of preventable morbidity and mortality in the world. First-line pharmacotherapies for the treatment of tobacco use disorder include nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. We provide an overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder.Areas covered: Randomized clinical trials published in English up to July 2015 were identified and reviewed through searches of PUBMED using the terms nicotine replacement therapy, bupropion SR, varenicline, smoking, and tobacco cessation.Expert opinion: Nicotine replacement has few contraindications and side effects and can be recommended to almost all tobacco users. Bupropion SR should be used with caution in patients with bipolar disorder or liver or kidney disease, and alternative treatments should be considered for patients with a history of seizures or who are at risk for seizures. The only contraindication for varenicline is an allergy to the medication, and nausea is the most common side effect. Varenicline can be used safely in patients with cardiovascular disease. Varenicline can be used in patients with stable psychiatric disease and safety can be ensured through close clinical monitoring.",
author = "Little, {Melissa A.} and Ebbert, {Jon O.}",
year = "2016",
month = "3",
day = "3",
doi = "10.1517/14740338.2016.1131817",
language = "English (US)",
volume = "15",
pages = "333--341",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The safety of treatments for tobacco use disorder

AU - Little, Melissa A.

AU - Ebbert, Jon O.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Introduction: Tobacco continues to be a leading cause of preventable morbidity and mortality in the world. First-line pharmacotherapies for the treatment of tobacco use disorder include nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. We provide an overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder.Areas covered: Randomized clinical trials published in English up to July 2015 were identified and reviewed through searches of PUBMED using the terms nicotine replacement therapy, bupropion SR, varenicline, smoking, and tobacco cessation.Expert opinion: Nicotine replacement has few contraindications and side effects and can be recommended to almost all tobacco users. Bupropion SR should be used with caution in patients with bipolar disorder or liver or kidney disease, and alternative treatments should be considered for patients with a history of seizures or who are at risk for seizures. The only contraindication for varenicline is an allergy to the medication, and nausea is the most common side effect. Varenicline can be used safely in patients with cardiovascular disease. Varenicline can be used in patients with stable psychiatric disease and safety can be ensured through close clinical monitoring.

AB - Introduction: Tobacco continues to be a leading cause of preventable morbidity and mortality in the world. First-line pharmacotherapies for the treatment of tobacco use disorder include nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. We provide an overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder.Areas covered: Randomized clinical trials published in English up to July 2015 were identified and reviewed through searches of PUBMED using the terms nicotine replacement therapy, bupropion SR, varenicline, smoking, and tobacco cessation.Expert opinion: Nicotine replacement has few contraindications and side effects and can be recommended to almost all tobacco users. Bupropion SR should be used with caution in patients with bipolar disorder or liver or kidney disease, and alternative treatments should be considered for patients with a history of seizures or who are at risk for seizures. The only contraindication for varenicline is an allergy to the medication, and nausea is the most common side effect. Varenicline can be used safely in patients with cardiovascular disease. Varenicline can be used in patients with stable psychiatric disease and safety can be ensured through close clinical monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84959527932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959527932&partnerID=8YFLogxK

U2 - 10.1517/14740338.2016.1131817

DO - 10.1517/14740338.2016.1131817

M3 - Review article

VL - 15

SP - 333

EP - 341

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -